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Abstract: Bites from elapid snakes typically result in neurotoxic symptoms in snakebite victims.
Neurotoxins are, therefore, often the focus of research relating to understanding the pathogenesis
of elapid bites. However, recent evidence suggests that some elapid snake venoms contain antico-
agulant toxins which may help neurotoxic components spread more rapidly. This study examines
the effects of venom from the West African black-necked spitting cobra (Naja nigricollis) on blood
coagulation and identifies potential coagulopathic toxins. An integrated RPLC-MS methodology,
coupled with nanofractionation, was first used to separate venom components, followed by MS,
proteomics and coagulopathic bioassays. Coagulation assays were performed on both crude and
nanofractionated N. nigricollis venom toxins as well as PLA2s and 3FTx purified from the venom.
Assays were then repeated with the addition of either the phospholipase A2 inhibitor varespladib or
the snake venom metalloproteinase inhibitor marimastat to assess whether either toxin inhibitor is
capable of neutralizing coagulopathic venom activity. Subsequent proteomic analysis was performed
on nanofractionated bioactive venom toxins using tryptic digestion followed by nanoLC-MS/MS
measurements, which were then identified using Swiss-Prot and species-specific database searches.
Varespladib, but not marimastat, was found to significantly reduce the anticoagulant activity of N.
nigricollis venom and MS and proteomics analyses confirmed that the anticoagulant venom com-
ponents mostly consisted of PLA2 proteins. We, therefore, conclude that PLA2s are the most likely
candidates responsible for anticoagulant effects stimulated by N. nigricollis venom.
Keywords: snakebite; Naja nigricollis; coagulopathy; varespladib; marimastat; nanofractionation;
mass spectrometry
Key Contribution: PLA2s from Naja nigricollis venom inflict anticoagulant effects on bovine plasma, the
effects of which are significantly reduced with the addition of the small molecule inhibitor varespladib.
1. Introduction
Snakebite has been defined by the World Health Organization (WHO) as a neglected
tropical disease since June 2017. Though estimates of global envenoming rates fluctuate
dramatically, it is thought that between 421,000 [1] and 2.7 million [2] people per year
are bitten by venomous snakes, resulting in an estimated 81,000–138,000 deaths annually.
Reliable estimates of snakebite cases are challenging to obtain due to data being reliant
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on geographically-focused surveys and hospital statistics [3], while issues arise from the
underreporting of snakebite incidences from both individuals and hospitals [4]. The most
recent efforts at mapping snakebite vulnerability place 92.66 million people as living in
areas vulnerable to snakebite, with the most vulnerable of these areas located in sub-
Saharan Africa [5].
Elapids (Elapidae: including cobras, mambas, and related species) are a venomous,
front-fanged family of snakes responsible for many snakebite cases in Africa. Bites from these
snakes often result in severe neurotoxic pathology, resulting in initial symptoms of ptosis
before progressing (in the worst of cases) to total respiratory paralysis and death [6,7]. Cobras
(Naja spp.) are a group of elapid snakes that display defensive hooding behaviour when
threatened, and bites from many species inflict neurotoxic symptoms typical of other elapid
venoms [8–10]. However, African spitting cobras (subgenus Afronaja), which can project their
venom as a defensive spray, more typically inflict bites that result in cytotoxic effects, such as
swelling and tissue necrosis, as well as haemostatic disturbances, such as abnormal blood
clotting [7,11–13]. The black-necked spitting cobra, Naja nigricollis, is a medically-important
species that inhabits a wide range across the central belt of Africa [14], and is thought to
be responsible for the majority of elapid bites in many of these areas [15–17]. Bites from
this species have been shown to result in local swelling and tissue necrosis, bleeding, and
blistering [11,13]. In vivo studies show that, when injected intradermally, the venom causes
oedema, blistering and necrotic lesions in a mouse model [18], and exhibits strong cytotoxic
effects on the myogenic cell line C2C12 [19].
Anticoagulant toxins may play an important role in certain elapid envenomings by
acting as a spreading factor for other components such as neurotoxins [20]. These toxins
cause anticoagulant effects via several mechanisms: through the inhibition of factor X or
thrombin, the lysis of fibrin, the activation of plasminogen and/or the inhibition of platelet
aggregation [21,22]. Several toxin families found in the venoms of cobras are thought to
exert functional effects consistent with causing anticoagulation. Phospholipases A2 (PLA2s)
from N. naja and N. haje venom have been previously demonstrated to inhibit platelet aggre-
gation [23,24] and thrombin [25], respectively. Cytotoxic three-finger toxins (3FTxs) from
N. atra and N. kaouthia venoms have been demonstrated to lyse erythrocytes [26], while
the cytotoxic 3FTx complex hemextin AB identified from the venom of the closely related
species Hemachatus haemachatus has been shown to inhibit the activity of the coagulation
component factor VIIa [27]. The apparent synergy between PLA2s and 3FTxs in N. mossam-
bica and H. haemachatus venom has been found to increase the potency of haemolytic venom
activity [28], and perhaps cytolysis in general [29]. Some snake venom serine proteases
(SVSPs), though not typically a major constituent of elapid venoms [30], can contribute to
coagulant activity through the activation of clotting factors V/Va and VIII/VIIIa, thereby
acting in a procoagulant manner [31]. Other SVSPs are anticoagulant via their cleavage of
fibrinogen, thus depleting the availability for fibrin formation caused by this activity [32].
Finally, snake venom metalloproteinases (SVMPs) from N. naja venom have been found
to cause delays in clotting time through the hydrolysis of haemoglobin [33]. However, in
combination, 3FTxs, PLA2s and SVMPs typically account for >95% of the total toxin content
of the majority of cobra venoms [29], and thus identifying the key toxins responsible for
anticoagulant venom effects remains challenging. Nonetheless, a recent study showed that
the PLA2 inhibitor varespladib was capable of effectively neutralising the anticoagulant
activity of many Afro-Asian elapids, including N. nigricollis [34], suggesting that this toxin
family may be of greatest importance.
The venom of N. nigricollis, like many elapid snakes [30], is predominantly composed
of 3FTxs and PLA2s [29,35]. Crude N. nigricollis venom shows the ability to cleave fib-
rinogen [36] and inhibit platelet aggregation [37], but the primary toxin thought to be
responsible for anticoagulation appears to be a multifunctional PLA2 named “CM-IV”.
Historical literature suggests that CM-IV causes anticoagulant effects via the inhibition of
the extrinsic coagulation cascade and the tenase and prothrombinase complexes [38–40],
and via non-enzymatic binding to clotting factor Xa [41],. In addition, and likely, secon-
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darily, four different 3FTxs found in N. nigricollis venom have been demonstrated to lyse
erythrocytes [42].
This study aims to reinvestigate the anticoagulant activity of venom from the medically-
important black-necked spitting cobra (Naja nigricollis) and identify the toxins responsible
for perturbing blood clotting. Crude venom activity was first analysed through a co-
agulation assay on bovine plasma [43], demonstrating a potent anticoagulant effect. A
two-fold approach was then used to identify coagulopathic toxins: i) nanofractionation of
N. nigricollis venom was performed followed by MS and proteomics-based identification of
anticoagulant venom toxins detected in the bioassay and ii) venom was separated by three
steps of chromatography into its main constituent parts, PLA2s and 3FTxs, and these toxins
were then assessed for anticoagulant activity, A schematic overview of the complete analyt-
ical and biochemical workflow including workflow explanation is provided in Figure 1.
Ultimately, the combination of these experimental approaches convincingly demonstrated
that PLA2s are responsible for disruptions in coagulant activity caused by N. nigricollis
venom and that this activity is effectively inhibited by varespladib.
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2. Results
2.1. Anticoagulant Effects of Crude N. nigricollis Venom and Quantification of Inhibition by Small
Molecule Toxin Inhibitors
To analyse the effects of N. nigricollis venom on blood coagulation, crude venom was
applied to citrated bovine plasma in a 384-well plate bioassay. The presence of crude
venom at assay concentrations of 0.2 µg/mL and 0.02 µg/mL, but not 0.002 µg/mL, was
found to significantly decrease coagulant activity as compared to control wells containing
PBS only (one-way ANOVA with multiple comparisons: F = 33.1, R2 = 0.67, p < 0.0001),
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confirming that N. nigricollis venom has a potent anticoagulant effect even at low doses
(Figure 2a). Next we tested the potential of toxin family-specific small molecule inhibitors
to inhibit the anticoagulant effect of N. nigricollis venom, and demonstrated that a 150 µM
concentration of the PLA2 inhibitor varespladib caused a significant decrease in anticoag-
ulant activity compared to crude venom (one-way ANOVA with multiple comparisons:
F = 8.67, R2 = 0.73, p = 0.01), but not a 450 µM concentration, though this did approach the
significance threshold (F = 8.67, R2 = 0.73, p = 0.08) (Figure 2b). Contrastingly, the SVMP
inhibitor marimastat showed no inhibition of anticoagulant venom activity at either of the
tested concentrations (F = 8.67, R2 = 0.73, p = 0.84; p = 0.97, for 150 µM and 450 µM, respec-
tively) (Figure 2b), indicating that SVMPs are not likely to be involved in the anticoagulant
activity of N. nigricollis venom.
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2.2. Identification of Anticoagulant Venom Toxins Via Nanofractionation, Bioactivity Testing
and Proteomics
To further explore the toxins responsible for anticoagulant venom effects, we next
applied an approach consisting of high-resolution LC fractionation (i.e., nanofractionation)
of venom (50 µL per injection at various concentrations) into a 384-well plate followed by
the use of the plasma coagulation assay. Venom was separated using HPLC, followed by a
post-column split in a 1:9 ratio, of which the smaller portion went to UV and MS detection,
while the majority went to the nanofractionation module, which enabled high-resolution
column eluate collection in serpentine-wise fashion onto 384-well plates. After performing
the coagulation bioassay on the plate with fractionated toxins, so-called bioassay chro-
matograms were constructed for which the coagulation bioassay signal was plotted (y-axis)
versus retention time of fractionation (x-axis).
The chromatographic bioassay profile of 1 mg/mL N. nigricollis venom (50 µg injection)
was defined by a broad negative peak at the time interval between 15.2–19.8 min (Figure 3,
for duplicate experiment see Figure S3). In this anticoagulation time frame, two clear peaks
were observed on the parallel UV chromatogram. The negative peak gradually decreased
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in width upon decreasing the venom quantity injected, and anticoagulant venom activity
could still be observed with a loading of just 2 µg venom. At venom concentrations of
0.04 and 0.2 mg/mL venom (2 and 10 µg loaded), the sharp anticoagulant peak shapes
allowed for correlation with the peaks observed in the UV trace (and from the MS trace,
which was also recorded). Based on this initial concentration series, a concentration of
0.2 mg/mL (10 µg injection) venom was chosen for later assessment of the inhibition
of anticoagulant venom toxins via the use of varespladib and marimastat. As an aside,
for all of the venom concentrations tested, the procoagulation bioassay chromatograms
revealed no procoagulant venom activity, thereby confirming that potent anticoagulant
venom activity is not masking any weakly procoagulant venom toxins.
Prior to performing toxin inhibition experiments, we first assigned accurate masses
to the venom components exhibiting anticoagulant activity in the plasma coagulation
assay. This was done by correlating bioactivity peaks in the bioactivity chromatograms
to the corresponding MS chromatogram based on elution time and peak shape of the
bioactive peaks. This method proved to be successful for masses up to 15 kDa. However,
larger toxins proved to be much more difficult to correlate because masses higher than
20 kDa did not appear in the MS chromatogram, most likely due to a lack of sensitivity
of the LC-MS caused by poor ionization or insufficient amounts of the relevant proteins.
The resulting mass spectrometry (MS) data is displayed in Figure 3 and consists of the
base peak chromatogram (BPC) (shown in black) and nine extracted ion chromatograms
(XICs) displayed in light green for acidic PLA2, dark green for basic PLA2 and red, orange,
purple and blue representing 3FTxs. By correlating the negative peak(s) in the bioassay
chromatograms with the parallel UV and MS chromatograms, accurate masses of the
anticoagulant toxins could be tentatively assigned.
In these analyses, several PLA2s closely coeluted and had masses of 13,245.80 Da
(coeluting around tR of 16.1 min) and 13,167.61 Da (tR of around 16.8 min). The MS data
(i.e., Base peak chromatogram (BPC)) matched in profile with the UV chromatogram data
(Figure 3). The peak observed at 27–28 min is the end of the gradient and considered
as waste from the column that was detected by MS. The three-finger toxins coeluted
around tR 15.7 to 18.5. From the MS data, there were seven 3FTxs detected and five of
them were successfully identified. The details of the 3FTxs identified are presented in
Table 1. Members of the SVMP toxin family are present at very low concentrations in
N. nigricollis venom, but due to their relatively high mass these proteins are difficult to
protonate and detect with LC-MS. Thus, the LC-MS method in this study was not further
used to characterize SVMPs. Bottom-up proteomics methods however do not have this
drawback (as the large protease toxins are, after RPLC separation, trypsin digested into
smaller peptides prior to MS analysis) and was used to successfully identify several SVMPs.
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Figure 3. Correlation of LC-UV and MS chromatogram and bioassay chromatogram of N. nigricollis
venom. (A) Base peak chromatogram (BPC), extracted ion currents (XIC), and (B) UV chromatogram
of N. nigricollis veno (1 g/mL, 50 µL injection volume, post-column split into 1:9 ratio of which
t e smaller portion went to and 254 nm recorded); and then to MS detection). (C) Su-
perimposed anticoa lati ioassay chromatograms resulting from analyses of serially diluted
N. nigricollis venom ranging from 1 mg/mL to 0.008 mg/mL (50 µL per injection). (D) Superim-
posed pro-coagulation bioassay chromatograms resulting from analyses of serial diluted N. nigricollis
venom ranging from 1 mg/mL to 0.008 mg/mL (50 µL per injection). Bioassay chromatograms can
be correlated to UV and MS chromatograms. For the pro-coagulation bioassay chromatograms, no
pro-coagulation activities were detected.
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Table 1. Overview of tentatively assigned venom toxins associated with the observed anticoagulation peaks. The table shows m/z values, including charge state measured for each m/z
value of intact toxins observed in MS, their retention times, and the calculated accurate mass for each toxin. Moreover, proteomics derived Mascot (Swiss-Prot) protein identification and
Mascot derived corresponding masses are shown, as are matches to the species-specific venom gland transcriptome databases. Hits were obtained by database searches of nanoLC-MS/MS
data measured from tryptic digests of the respective venom toxins after nanofractionation and collecting these venom toxins from their respective wells in which they were fractionated.
Retention Time (min) m/z Value (Charge) MS Accurate Mass (Da) Mascot Protein Hits (ProteinIdentification) Mascot Exact Mass (Da)
Species-Specific
Database Hits Toxin Class
15.7 1036.75(+7) 7247.21 Three-finger toxin N.A. N.A. 3FTx
13,217 Basic Phospholipase A2 (B1) ** N.A. N.A. PLA2
16.1 1473.54 (+9) 13,245.80
PA2B4_NAJNG
(Naja nigricollis) Phospholipase A2
Basic (B2) **
13,244.90 T0927_T1551_T1904_T2072 PLA2
13,184 Acidic Phospholipase A2 (A1) ** N.A. N.A. PLA2
13,256 Acidic Phospholiase A2 (A2) ** N.A. N.A. PLA2
16.8 1464.96 (+9) 13,167.61 PA2A1_NAJMO (Naja mossambica)Acidic Phospholipase A2 CM-I
13,195.75 T1049_T1649 PLA2
16.8 959.32(+7) 6705.26 3SA4_NAJMO (Naja mossambica)Cytotoxin 4 6702.34 T1903_R_6_8306_350 3FTx
17.0 965.90(+7) 6751.26 3SA9_NAJNA (Naja naja) Cytotoxin9 (3FTx group 2) ** 6750.36 * T0802_R_6_4763_L_609 3FTx
17.2 956.17(+7) 6683.19 3SAN_NAJNG (Naja nigricollis)Naniproin 6682.41 T2051_R_3_6355_L_312 3FTx
17.4 974.48(+7) 6811.31 3SA5_NAJAT (Naja atra) Cytotoxin 5 6810.35 * T2073_R_2_4857_L_300 3FTx
17.7 984.77(+7) 6883.37 Three-finger toxin (3FTx group 2) ** N.A. N.A. 3FTx
18.0 975.04(+7) 6815.28 3SA1_NAJPA (Naja pallida)Cytotoxin 1 (3FTx group 2) ** 6814.31 T0939_T1746_R_11_8132_L_555 3FTx
6817 Three-finger toxin (3FTx group 1) ** N.A. N.A 3FTx
* calculated without signal peptide, ** protein was obtained from purified sample, N.A. = not applicable.
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For the last step, to identify the coagulopathic venom toxins observed in the plasma
coagulation assay after nanofractionation, selected wells containing the anticoagulation
bioactive toxins were subjected to tryptic digestion. The trypsin-digested contents of each
anticoagulant bioactive well (between retention times 16.0–19.3 min) were analysed using
nanoLC-MS/MS and the resulting data were matched against proteins contained in the
Swiss-Prot database and in a species-specific database derived from amino acid translations
of venom gland transcriptomic data [29]. The protein search from the Swiss-Prot database
resulted in 3FTxs, acidic and basic PLA2s, L-amino-acid oxidase (LAAO), SVMPs, and
venom nerve growth factor (vNGF) (Figure 4). The species-specific database searches
resulted in 3FTxs, acidic and basic PLA2s, SVMPs, C-type lectin, cysteine-rich secretory
protein (CRISP), Kunitz-type serine protease inhibitor, and vNGF (Figure 5). In total, from
all wells, we obtained 43 protein matches from the Swiss-Prot database (Figure S1) and 32
from the species-specific transcriptomic database (Figure S2). While the results obtained
were complimentary, the discrepancy in number between the two searches is likely the
result of the bioactive compounds not having an exact match in the Swiss-Prot database, but
instead exhibiting high sequence similarity to several venom toxins deposited in Swiss-Prot
from related snake species.
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Many toxins from similar species may also appear as a result, especially for PLA2, 
when using this database for searches. This for example resulted in proteins from other 
species appearing in the search results, such as PA2A1_NAJMO from N. mossambica. The 
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Figure 4. Proteomic annotation of N. nigricollis venom using Mascot software and the Swiss-Prot database. The protein
score represents the probability that designated proteins, defined by elution time, are present in the sample.
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time, are present in the sample.
The toxin that eluted around tR 16.1 min matched the basic PLA2 PA2B4_NAJNG
from N. nigricollis, and the toxin that eluted around tR 16.8 min matched the acidic PLA2
CM-I (PA2A1_NAJMO) from N. mossambica, as determined by searches of the Swiss-Prot
database. Searches of the proteomics data against the species-specific database yielded sim-
ilar results, with the toxins eluted around tR 16.1 min and 16.8 both matching PLA2 toxins
(transcriptome dat base ID T0927_T1551_T1904_T2072 and T1049_T1649, resp ctively). A
detailed overview of the PLA2s identified from the MS and proteomics data can be found
in Table 1.
Many toxins from similar species may also appear as a result, especially for PLA2,
when using this database for searches. This for example resulted in proteins from other
species appearing in the search results, such as PA2A1_NAJMO from N. mossambica. The
species-specific database is a series of protein sequences that i derived from a venom
gland transcriptome study. This study was conducted by the Liverpool School of Trop-
ical Medicine, UK [44–46]. The protein sequences in the species-specific database for N.
nigricollis contained 38 proteins while the protein sequences in the Swiss-Prot database for
N. nigricollis contained only 8 proteins. The PLA2s are under-represented in the species-
specific database results (see Figure 5) because the species-specific database predominantly
retrieved 3FTxs, which is a consequence of the species-specific database containing pre-
dominantly 3FTx protein sequences.
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2.3. Assessing Inhibition of Nanofractionated Toxins by Varespladib and Marimastat
The two main PLA2-mediated anticoagulation peaks observed (PA2B4_NAJNG
and PA2A1_NAJMO), within a retention time frame of 15.2–17.2 min, were unsurpris-
ingly not inhibited by the SVMP inhibitor marimastat, but both were dose-dependently
inhibited by the PLA2 inhibitor varespladib (Figure 6, duplicate experiment see
Figures S4 and S5). At the maximum concentration tested (20 µM), both bioactivity
peaks were almost fully neutralised by varespladib, as evidenced by notable decreases
in both negative peak height and peak width. However, the data presented here clearly
show that SVMPs are not associated with the coagulant activity of N. nigricollis venom
under these conditions, as treatment with marimastat had no effect on the resulting
coagulation profiles. Meanwhile, SVMPs were not detected using LC-MS to obtain
intact masses (due to high mass/poor ionisation), this toxin family was detected after
trypsin digestion of the fractions from the nano-LC separation. This data showed that
N. nigricollis SVMPs eluted between 18.1 and 18.9 min with no corresponding pro- or
anticoagulation activity observed in the bioassay.
2.4. Anticoagulant Effects of Isolated and Purified N. nigricollis Toxins
The ability of varespladib to reduce the anticoagulant activity of N. nigricollis
venom indirectly suggests that PLA2 toxins play a major role in perturbing coagula-
tion, as previously proposed [34]. To investigate this further, the main constituents
of N. nigricollis venom were purified in mg quantities using gel filtration, cation
exchange and reverse-phase chromatography. These formed four groups: Acidic
PLA2 (two forms with masses 13,184 and 13,256 Da, designated A1 and A2), basic
PLA2 (two forms with masses 13,217 and 13,247 Da, designated B1 and B2 and the
latter equivalent to the XICs displayed in dark green in Figure 3), 3FTx group 1 (mass
6816 Da, equivalent to the XICs displayed in red in Figure 3), and 3FTx group 2
(containing three proteins of mass 6884, 6818 and 6752 Da, likely to be equivalent to
the XICs displayed in orange, red and blue respectively in Figure 3). These proteins
were tested at 1 µg/mL alongside crude venom across two coagulation assays and
the results standardized against the activity of the whole venom sample. Both acidic
and basic PLA2s exhibited anticoagulant activity (Figure 7), with the acidic types
exhibiting approximately 50% of the anticoagulant activity of the whole venom, and
the basic types approximately 99% activity. Neither 3FTx groups showed any antico-
agulant activity in relation to the crude venom at the concentration used here. This
work strongly implicates basic PLA2s as being the main toxins responsible for venom-
induced anticoagulation in N. nigricollis venom, aided by a weaker contributory
activity from acidic PLA2s.
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Figure 6. Correlation of UV chromatogram and small molecule inhibition bioassay chromatogram of
N. nigricollis venom. Superimposed bioassay chromatograms resulting from analyses of N. nigricollis
venom (0.2 mg/mL, 50 µL injection volume) in the presence of different concentrations of (A) vare-
spladib or (B) marimastat. Bioassay chromat grams are correlated to UV chromatograms in the
figure. For the pro-coagulation bioassay chromatograms, no pro- oagulation activities w re detected.
Varespladib effectively inhibited anticoagulant venom effects (highlighted in the green rectangle) in a
dose dependent manner with inhibitor concentrations ranging from 20 µM to 0.032 µM. Marimastat
had no effect on inhibition of anticoagulant venom activity (the retention time where SVMPs are
detected using tryptic digestion and nano-LC separation are highlighted in the blue rectangle) at the
tested inhibitor concentrations of 20 µM to 0.032 µM.
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Figure 7. Isolated basic phospholipase A2s (PLA2s) show anticoagulant activity comparable to that
of crude N. nigricollis venom. A1-acidic PLA2 1 (mass 13,184 Da), A2-acidic PLA2 2 (mass 13,256 Da),
B1-basic PLA2 1 (mass 13,217 Da), B2-basic PLA2 2 (mass 13,248 Da), 3FTx1-three-finger toxin (3FTx)
group 1 (mass 6817 Da), 3FTx2–3FTx1–3FTx group 2 (masses 6885, 6818 and 6753 Da). Activity was
calculated as the average control area under the curve (AUC) minus the sample AUC, standardized
by the mean crude venom AUC, of 2 assays where samples were run at 0.01 mg/mL. Error bars
represent the standard error of the mean (SEM).
3. Discussion
Our findings demonstrate that Naja nigricollis venom displays considerable anticoag-
ulant activity, as shown by coagulation assays utilising bovine plasma, and that despite
3FTxs being the dominant constituents of this venom, this anticoagulant activity observed
is caused by PLA2 toxins, as exhibited through testing of N. nigricollis toxins isolated by
nanofractionation or standard chromatographic means. These findings were supported
by the reduction in activity observed following application of the small molecule PLA2
inhibitor varespladib to crude venom and nanofractionated toxins. These results correlate
with previous literature that demonstrate the anticoagulant ability of cobra venoms [34,47]
and cobra venom PLA2s [23,40,47,48]. Indeed, venom PLA2s from the Naja genus have
previously been found to disrupt haemostatic regulations via the inhibition of both throm-
bin [25] and platelet aggregation [23,24]. Identification of PLA2s as the main anticoagulant
components in N. nigricollis venom is also consistent with previous nanofractionation and
assaying of viper venoms, in which PLA2s are the primary anticoagulant toxins in Bothrops
asper, Calloselasma rhodostoma, Daboia russelii and Echis ocellatus venoms [46].
PLA2s in N. nigricollis have previously been shown to inhibit the prothrombinase
and tenase complexes to prevent coagulation [38–41], making it unsurprising that they
should be identified here as the main anticoagulant components of the venom. Acidic
and basic PLA2s can both act enzymatically in this respect, acting on the TF-VIIa complex,
but in addition basic PLA2 can act non-enzymatically through binding to Factor Xa and
preventing its binding with Factor Va [38,41,48]. This enhanced anti-coagulation activity
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of the basic form, compared with that of the acidic, is reflected in the results we obtained
from testing purified the PLA2s purified from N. nigricollis venom (Figure 7).
Despite PLA2s being identified as the main venom component responsible for venom-
induced coagulopathy caused by N. nigricollis venom, the role of 3FTxs and/or the syn-
ergistic effects of PLA2s and 3FTxs in elapid venoms on haemostasis remains poorly
defined. Our results suggest that, at least in the case of N. nigricollis, 3FTxs in general
appear to have little to no impact on the clotting of plasma. The two 3FTx groups tested
here constitute >90% of the 3FTx components of this venom. Naja 3FTxs may still play
a role in disrupting haemostasis, however, as they have previously been demonstrated
to lyse erythrocytes [25,38], and enhance the potency of haemolytic venom activity when
in combination with PLA2s from N. mossambica and H. haemachatus venoms [27]. We also
found no evidence that the SVMPs in N. nigricollis venom perturb coagulation. This is
perhaps surprising since SVMPs from Naja atra venom have previously been shown to
inhibit blood coagulation [49], and that various other P-III SVMPs are known to disrupt
coagulation through the activation of prothrombin and/or factor X, cleavage of fibrinogen
and/or inhibition of platelet aggregation [50]. It may well be that such activity has not been
detected here because of the very low levels of SVMP in the venom of Naja nigricollis (<5%
of total venom proteins) [29,35] or the likelihood that SVMP activity has been disrupted by
the conditions of reverse-phase chromatography utilised in this study.
The ability of the small molecule PLA2 inhibitor varespladib to inhibit the antico-
agulant activity of N. nigricollis venom is consistent with findings from the literature
demonstrating the neutralization of PLA2-mediated coagulopathy of the venoms of several
vipers [51–54], the elapid Oxyanurus scutellatus [51], and many Afro-Asian elapids [34] by
varespladib. Varespladib binds to the fatty acid substrate site in PLA2 [55], which would
explain its inhibition of the enzymatic component of the anti-coagulant action of acidic
and basic PLA2s, but in this way it may also prevent basic PLA2 binding to Factor Xa
through steric hindrance, thus also inhibiting this particular mechanism of anti-coagulation.
The PLA2 His47 amino acid residue, which plays an essential role in the interaction of
varespladib and PLA2s, was found in both proteins identified by Swiss-Prot as the PLA2s
PA2B4_NAJNG and PA2A1_NAJMO. In addition to the varespladib-PLA2 inhibition ob-
served here and elsewhere relating to anticoagulant venom activity, there is also evidence
that varespladib may aid in the inhibition of PLA2-mediated neurotoxicity, as seen in the
elimination of mortality in mice envenomed by the neurotoxic snakes Micrurus fulvius,
Oxyuranus scutellatus and Vipera berus nikolskii [56–60]. Combined, these data suggest that
varespladib is a highly promising future treatment option for tackling snakebite.
4. Materials and Methods
4.1. Chemical and Biological Reagents
Water was purified with a milli-Q Plus system (Millipore, Amsterdam, The Nether-
lands). DMSO was supplied by Redel-de-Haen (Zwijndrect, The Netherlands). Acetonitrile
(ACN) was obtained from Concord, NC, USA; UPLC/MS grade). Formic acid (FA, MS
grade) and acetic acid (AA) were purchased from Biosolve (Valkenswaard, The Nether-
lands). CaCl2, K2HPO4, KH2PO4, NH4HCO3, Phosphate Buffer Saline (PBS) tablets, and
other salts used for buffer preparation were of analytical grade and purchased from
trusted suppliers (Merck, Kenilworth, UK; Fluka, Bucharest, Romania; or Sigma-Aldrich,
Darmstadt, Germany). The PLA2 inhibitor varespladib, SVMP inhibitor marimastat, and
iodoacetamide were purchased from Sigma-Aldrich.
Lyophilized N. nigricollis venom pooled from multiple animals of Nigerian origin was
provided by the Centre for Snakebite Research and Interventions Herpetarium (Liverpool
School of Tropical Medicine, Liverpool, UK) and stored long-term at 4 ◦C. Stock solutions
of the crude venom (5.0 ± 0.1 mg/mL) were prepared in water before analysis, and then
aliquoted and stored at −20 ◦C until use. Bovine plasma (500 mL bottles) used in the
nanofractionation assays was purchased from Biowest (Nuaille, France), that for assay of
venom and purified toxins was provided by Equitech-Bio (SBPUC35-0100). The plasma
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was defrosted in a water bath at 37 ◦C, centrifuged at slow speed, and then rapidly
aliquoted (approximately 10 mL in 15 mL falcon tubes) and stored at −80 ◦C prior to
use. Lyophilized trypsin GoldTM (mass spectrometry grade) enzyme was purchased from
Promega Corporation, Madison, WI, USA. The trypsin was reconstituted in 50 mM acetic
acid to obtain a 1 µg/µL concentration, which was aliquoted and stored at −80 ◦C until use.
4.2. Coagulopathic Activity of Crude N. nigricollis Venom and Assessment of Inhibition with
Varespladib and Marimastat
Plasma clotting assays on crude N. nigricollis venom and toxins purified by chromatog-
raphy were performed on citrated bovine plasma using previously described protocols [61].
Thawed, plasma was centrifuged at 2000× g for 4 min to remove precipitates. For crude
venom assays, 10 µL of N. nigricollis venom at concentrations of 1 µg/mL, 10 µg/mL and
100 µg/mL in PBS (final assay concentrations of 0.002, 0.02 and 0.2 µg/mL respectively)
was pipetted in quadruplicate onto a Greiner Bio-One clear 384-well microplate, while
10 µL PBS was pipetted into control wells. To all wells, a 20 uL solution of 20 mM calcium
chloride was added using a Thermo Scientific™ Multidrop™ 384 Labsystems multidrop
pipettor (Oxford, UK). The multidrop was then flushed with deionized water before being
used to add 20 µL of plasma into each well. Plates were read kinetically at a wavelength of
595 nm and a temperature of 25 ◦C using a FLUOstar Omega plate reader (Aylesbury, UK),
with run time set to 110 cycles at a cycle time of 80 s. Clotting activity was measured as
the area under the absorption curve (AUC) from 0 to 100 min, calculated by the Graphpad
Prism v. 8.0 software.
For assays involving inhibitors, 5 well types were set up: (i) venom + inhibitor,
consisting of 1 µL of crude 100 µg/µL N. nigricollis venom (final concentration in the assay
2 µg/mL), 3.75 µL of the SVMP inhibitor marimastat (Sigma-Aldrich, M2699-5MG) or PLA2
inhibitor varespladib (Sigma-Aldrich, SML1100-5MG) at 2 mM or 6 mM (final concentration
in the assay, 150 and 450 µM), and 5.25 µL PBS, (ii) venom control, containing 1 µL of crude
100 µg/µL N. nigricollis venom and 9 µL PBS, (iii) inhibitor control: 3.75 µL of marimastat
or varespladib at 2 mM or 6 mM (final concentration in the assay, 150 and 450 µM), and
6.25 µL PBS, (iv) Dimethylsulfoxide (DMSO) control: 3.75 µL of the reconstituting solvent
for the inhibitors, DMSO, plus 6.25 µL PBS, (v) negative control: 10 µL PBS. Wells were
pipetted into a 384-well plate in quadruplicate after being incubated for 30 min at 37 ◦C,
followed by the addition of 20 µL 20 mM calcium chloride and 20 µL bovine plasma. The
absorbance of the plasma was then read at 595 nm on a FLUOstar Omega plate reader at
25 ◦C.
4.3. HPLC-MS-Nanofractionation and Simultaneous Bioassay of N. nigricollis Venom
Separation of venom toxins for the post-column bioassays was carried out by LC
with high-resolution nanofractionation in parallel to MS analysis. Samples were injected
with a Shimadzu SIL-20A autosampler, and the separation was performed with an LC
system controlled via Shimadzu Lab Solution software. The gradient was set using a
binary Shimadzu LC-20AB pump (A and B) at a total flow rate of 0.5 mL/min. Mobile
phase A was water-ACN-FA (98:2:0.1, v/v/v) and mobile phase B was water-ACN-FA
(2:98:0.1, v/v/v). The following gradient was used: 0% to 10% B (10 min), 10% to 95%
B (20 min), 95% B (2 min), 90% to 0% B (7 min), 0% B (2 min). A 100 × 4.6 mm ID
analytical column packed with Xbridge BEH300 reversed-phase C18 material (3.5 µm)
was used for separation. The column eluate was split in a 1:9 ratio using a low-dead-
volume flow splitter. The smaller flow part after the split (0.05 mL/min) was directed via
a Shimadzu SPD 20A UV-Vis detector (’s-Hertogenbosch, The Netherlands) with dual-
wavelength (220 nm and 254 nm) measurement to a Bruker Maxis HD Mass Spectrometer
(Bruker Daltonics, Bremen, Germany). The larger part of the eluate split was fractionated
(6 s/well) onto transparent 384-well plates (Grenier Bio-One, Alphen aan den Rijn, The
Netherlands) by use of a FractioMateTM FRM100 nanofraction collector (SPARK-Holland
& VU, Netherlands, Emmen & Amsterdam) controlled by FractioMator software or by
a modified Gilson 235P autosampler controlled by in-house written Ariadne software.
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After nanofractionation, the plates were vacuum centrifuged overnight to dryness at room
temperature using a Christ Rotational Vacuum Concentrator RVC 2-33 CD Plus (Salm
en Kipp, Breukelen, The Netherlands) with integrated cooling trap operating at −80 ◦C.
The plates were then stored at −80 ◦C until bioassayed or proteomics experiments were
performed. For mass analysis, the Maxis HD mass spectrometer was equipped with an
electrospray ionization source (ESI) and operated in positive ion mode. The parameters
of the ESI source were: source temperature, 180 ◦C; desolvation temperature of 180 ◦C;
capillary voltage of 4500 V; a gas flow of 4 L/min. The monitored mass range was m/z
500–3000 with a data-sampling time of 1 s. Protein masses (Da) were calculated using Data
Analysis 5.0 (Bruker, Darmstadt, Germany) software.
The venom dilution test was important for determining optimum venom concentration
for subsequent analyses, for which the venom concentration that exhibited sharp bioassay
peaks was chosen. These sharp peak(s) were desired for the subsequent small molecule
inhibitory assays as in this way, the effect of varespladib and marimastat could most
sensitively and effectively be assessed. A series of venom concentrations (1 mg/mL;
0.2 mg/mL; 0.08 mg/mL; 0.04 mg/mL; and 0.008 mg/mL) was made by diluting 5 mg/mL
venom stock solution with Milli-Q water. These venom solutions (50 µL) were injected into
the HPLC-MS system equipped with a nanofractionation module. Nanofractionated well
plates were freeze-dried, after which the coagulation activity assay was performed on each
plate. The resulting bioassay chromatogram from the venom dilution experiments were
superimposed on UV and MS traces.
The resulting bioassay chromatograms for measuring any evidence of procoagulation
and anticoagulation were generated and processed as follows: measurement of each
plate consisted of a kinetic loop measurement with 80 readings of the complete plate at
an interval of 15 s per reading. For plotting the procoagulant bioassay chromatograms,
the average rate of the coagulation curve measured for each well from reading 1 to 15
was used from the kinetic loop data. This was achieved by plotting the procoagulation
bioassay chromatograms as bioassay signal (y-axis) against fraction time (x-axis), which
gave resembled bioassay chromatograms. This resulted in positive peaks for eluted toxins
with pro-coagulatory effects (though none were observed). For the anticoagulation bioassay
chromatograms, the last absorbance reading (i.e., reading 80) of each well was plotted as
the y-axis in combination with fractionation time on the x-axis. Eluted venom toxins with
an anticoagulation effect showed up as negative peaks in these bioassay chromatograms.
4.4. Assessment of Inhibition of Nanofractionated Anticoagulant Toxins with Varespladib
and Marimastat
All measurements of coagulation activity were carried out in freeze-dried 384-well
plates in duplicate. The plates were first incubated at room temperature for assay prepa-
ration. To initiate the coagulation process, the mixing of plasma with calcium chloride
solution was carried out by transferring 20 µL of 20 mM calcium chloride solution to
the freeze-dried plate with 20 µL citrated bovine plasma using the Thermo Scientific
MultidropTM pipetting robot. Serial dilutions (0.16 µM; 0.8 µM; 4 µM; 20 µM; and 100 µM)
of varespladib and marimastat were made in PBS. Next, 10 µL of each inhibitor solution
was added to rows 8-18 of nanofractionated plates prior to further bioassay preparations
and measurements. Additionally, PBS was used as a negative control in row 4–7 and in
rows 19–22. The plate was spun down by centrifuging for 2 min and then incubated at
room temperature for 30 min with gentle shaking. The CaCl2 was added to corresponding
well to perform the coagulation assay, resulting in final assay concentrations of varespladib
and marimastat of 0.032 µM; 0.16 µM; 0.8 µM; 4 µM; and 20 µM. Thereafter, plate ab-
sorbance was measured at a wavelength of 595 nm by a Thermo Scientific Varioskan LuxTM
Plate reader using SkanIt 4.1 software. Measurements were performed in one kinetic loop
consisting of 80 readings, within 1.5 h. Two forms of data processing were carried out to
produce different representations of the coagulation chromatograms: a single reading at
80th reading (1.5 h) for anticoagulation, the slope of a reading range for determining any
pro-coagulation [62].
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4.5. In-Solution Tryptic Digestions from Nanofractionated 384-Well Plates
Vacuum centrifuged nanofractionated well plates were defrosted at room temperature
and the contents of the wells whose contents were selected for digestion were dissolved
in 40 µL milli-Q water. The plates were then spun down at 1000× g for 30 s using a plate
centrifuge (Eppendorf® Centrifuge 5810R), followed by shaking at 60 RPM for 30 min on a
plate shaker (IKA® KS 4000 IC Control). Digestion buffer was prepared by mixing reducing
agent (0.5% (v/v) β-mercaptoethanol in milli-Q water and AmmBi buffer pH 8.2 (25 mM
ammonium bicarbonate) at a 1:9 ratio. For each sample, an Eppendorf tube was filled
with 50 µL digestion buffer, before the addition of 30 µL of re-dissolved venom protein
sourced from each well of the well plate, followed by vortexing for 10 s. The samples were
then incubated at 95 ◦C for 10 min for reduction using a dry block heating thermostat
(Biosan® Bio TDB-100). Thereafter, 9 µL of alkylation agent (100 mM iodoacetamide)
was added to each sample followed by incubation in the dark at room temperature for
30 min. Trypsin stock solution was diluted with AmmBi buffer pH 8.2 to obtain a 0.1 µg/µL
working concentration and 5 µL added to each Eppendorf tube, followed by vortexing
and incubation at 37 ◦C for 3 h. An additional 5 µL of trypsin solution was then added to
each sample prior to incubation at 37 ◦C overnight. Subsequently, 10 µL of 5% formic acid
solution was added to each tube to terminate the digestion process. The resulting samples
were transferred to autosampler vials and analysed by nanoLC-ESI-MS/MS according to
method in Section 4.6.
4.6. Proteomics of Coagulopathic Venom Toxins
For proteomics analysis, an Ultimate 3000 nano HPLC module (Thermo Scientific,
Waltham, MA, USA) coupled to a Bruker Tims-TOF Mass Spectrometer (Bruker Daltonics,
Bremen, Germany) was used. Samples were injected with a WPS-3000(RS) autosampler,
and nanoLC separations were performed with a nanoLC system controlled via Chromeleon
7.2 SR4 MUb software. The gradient used was set using a nanoLC binary pump (A and B)
at a total flow rate of 0.5 µL/min. Mobile phase A was water-FA (100:0.1 v/v), and mobile
phase B was water-ACN-FA (20:80:0.1, v/v/v). The system was also equipped with a
loading pump, for which solvent water-ACN-FA (99:1:0.05 v/v/v) was used. The following
gradient was used: 1% B (10 min), 1%–20% B (5 min), 20%–50% B (30 min), 50%–85%
B (1 min), 85% B (5 min) 85%–1% B (0.5 min), 1% B (9.5 min). For sample trapping, an
Acclaim PepMap 100 reversed-phase C18 trapping column (particle diameter 5 µm and
column dimensions of 5 × 0.3 mm) was used. An Acclaim PepMap 100 reversed-phase C18
analytical column (particle diameter 2 µm and column dimensions of 150 × 0.75 mm), was
used to subsequently separate the peptides in the samples. Both the analytical column and
the trapping column were placed in a column oven of which the temperature was set at 45
◦C. The column eluate was transferred to a Bruker TIMS-TOF Mass Spectrometer, equipped
with a captive spray ionization (CSI) source in positive ion mode. The parameters of the
CSI source were: source temperature, 150 ◦C; desolvation temperature, 180 ◦C; capillary
voltage, 1300 V; gas flow, 3 L/min. The monitored mass range was m/z 300–3000 with a
data-sampling time of 0.5 s. The collision energy was 10 eV with pre-pulse storage 10 µs.
The raw MS/MS data from the nanoLC-ESI-MS/MS analyses were extracted using
Bruker Data Analysis 5.0 and converted into deconvoluted extracted ion chromatograms
(XICs). These deconvoluted XICs were then converted into Mascot generic format (MGF)
files using Data Analysis 5.0 and an in-house written script for automatization of this
process. The script contained instruction and parameters for deconvoluting the spectrum
included. The resulting MGF files were uploaded to Mascot to be used in database searches
against two different databases: the Swiss-Prot database and a species-specific database
for N. nigricollis from LSTM, UK [63]. The parameter used at Mascot searches depends
on the protein digestion method. To achieve consistent results, this following parameter
was used: (i) since iodoacetamide was used as an alkylating agent then fixed modification:
carbamidomethyl (C) was chosen (add 34 Da to methionine residue); (ii) the variable
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modification: amidated (C-term) and methionine oxidation (M), (iii) peptide tolerance of
±0.1% and MS/MS tolerance of ±0.05 Da, (iv) peptide charge of +1, +2, and +3.
All wells of proteins nanofractionated between retention times 16.0–19.3 min were
analysed (nanofractionation resolution 6 s) using proteomics approaches. The two database
searches using the same proteomics data yielded complementary results. The species-
specific database has the advantage that it exactly matches the searched proteomics data
with the corresponding transcriptomics data. This way only exactly matching results are
retrieved. The species-specific database contains 21 three-finger toxin entries, but it does
not provide additional valuable information that is available in Swiss-Prot. The Swiss-Prot
data base can provide extra information such as location of disulphide bridge, sequence
of signal-peptide, and protein mass. Therefore, in this study proteomics searches were
done using both databases in order to achieve results from the two database searches that
are complementary to each other. The species-specific database was also able to detect
minor venom toxins that were not picked up by the LC-MS measurements (such as CRISP,
NGF, SVMPs). On the other hand, the Swiss-Prot database provided cross-species searches
which were useful for gaining a better understanding of the active toxin enzymes eluting
at the anticoagulation bioactivity peak retention times.
4.7. Chromatographic Isolation of N. nigricollis Venom Components
To confirm the proteomic identification of venom components responsible for anticoag-
ulant activity in N. nigricollis venom, the major venom constituents (3FTxs and PLA2s) were
isolated using standard chromatographic methods. For the first step in the purification,
40 mg of N. nigricollis [Nigeria] venom dissolved in PBS was subjected to gel filtration
chromatography on 120 mL column of Superdex 75 [Cytiva]. The column was operated at
1 mL/min using PBS as buffer. This separated the high molecular weight material (SVMPIII
and LAAO) from the 3FTx and PLA2s; the latter two toxin groups eluted together as a
large single peak. This combined 3FTx, PLA2 material was dialysed against 50 mM sodium
phosphate, pH 5.8 and loaded on to a 4.7 mL cation exchange column (Hi-Screen SP, Cytiva)
and the toxins were then separated with a 0–0.7 M gradient of NaCl in 50 mM sodium
phosphate, pH 5.8. The main toxins eluted in the order acidic PLA2 (two forms) 3FTx group
1, 3FTx group 2 (containing three forms) and finally basic PLA2 (two forms). Following
dialysis into PBS, the 3FTx fractions were used directly for anti-coagulation studies. Acidic
and basic PLA2s were further purified using reverse-phase chromatography. Thus, 1 mg
of each was separately loaded onto a Phenomenex Jupiter C4 column [250 × 4.6 mm] and
then eluted using a 0–70% gradient of acetonitrile in 0.1% TFA. The solvent was removed
by rotary evaporation, avoiding complete drying, and then reconstituted in PBS. Purified
proteins were run on two plasma assays as per 4.2. at 1 µg/mL against 2 µg/mL (final
concentrations) crude N. nigricollis venom in replicates of 8. Anticoagulant activity of
isolated toxins was determined as a percentage of that of the crude venom.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/toxins13050302/s1, Figure S1: Detailed results of proteomics searches using Mascot software
against the Swiss-Prot Database to identify anticoagulant venom proteins, Figure S2: Detailed
results of proteomics searches using Mascot software against the N. nigricollis species-specific venom
gland transcriptome-derived database. Figure S3: Duplication results of superimposed pro- and
anticoagulation bioassay chromatograms resulting from analyses of serial diluted N. nigricollis
venom ranging from 1 mg/mL to 0.008 mg/mL (50 µL per injection). Figure S4: Duplication
results of superimposed bioassay chromatograms resulting from analyses of N. nigricollis venom
(0.2 mg/mL, 50 µL injection volume) in the presence of different concentrations of varespladib.
Figure S5: Duplication results of superimposed bioassay chromatograms resulting from analyses of
N. nigricollis venom (0.2 mg/mL, 50 µL injection volume) in the presence of different concentrations
of marimastat.
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